Karyopharm: XPORT-EC-042 Phase 3 hindi naabot ang PFS endpoint

Ang Phase 3 XPORT-EC-042 trial ng selinexor maintenance sa TP53 wild-type endometrial cancer ay hindi nakamit ang pangunahing PFS endpoint. Isang numerical trend na pabor sa selinexor ang nakita sa mITT population (HR 0.76, p=0.0791) ngunit hindi umabot sa statistical significance. Ang kumpanya ay magpapakita ng buong data sa isang hinaharap na medical meeting at sinasabi na ang mga resulta ay hindi nakakaapekto sa iba pang ongoing selinexor trials.

Mahahalagang fact

Na-file: Hul 31, 2026, 12:30 PM
Kaganapan: Topline na resulta
Direksyon: Negatibo
Kumpanya: KPTIKaryopharm
Asset: selinexor
Pinagmulan: SEC 8-K
Kumpiyansa: May source
pagpapatala ITT: 257
pagpapatala mITT: 220

Sipi mula sa source

8-K false 0001503802 0001503802 2026-07-30 2026-07-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2026 Karyopharm Therapeutics Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-36167 26-3931704 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 85 Wells Avenue , 2nd Floor Newton , Massachusetts 02459 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (617) 658-0600 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-

SEC 8-K